Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Recently, Sanofi (SNY - Analyst Report) received some encouraging news with the European Commission (EC) approving its candidate, Lemtrada, for adults suffering from relapsing remitting multiple sclerosis (RRMS).

The approval did not come as a surprise as the European Medicines Agency's Committee for Medicinal Products for Human Use had recommended the approval of Lemtrada in Jun 2013.

The CHMP issued a positive opinion on Lemtrada based on two pivotal phase III trials, which were completed in 2011. In the first study, CARE-MS I, Lemtrada met the first primary endpoint. Results showed that treatment with two annual cycles of Lemtrada as compared to Rebif resulted in a 55% reduction in the relapse rate over the two-year span of the study.

In the second study, CARE-MS II, Lemtrada met both the primary endpoints. Results showed that treatment with Lemtrada resulted in a 49% reduction in the relapse rate compared to Rebif, over a two-year period.  Additionally, Lemtrada showed a 42% reduction in the risk of sustained accumulation (worsening) of disability.

We remind investors that Lemtrada is under review for the above mentioned indication in the U.S. The U.S. Food and Drug Administration (FDA) is expected to render a decision on Lemtrada’s marketing application towards the end of this year.

We note that Lemtrada is the second RRMS drug from Sanofi to receive EC approval in the last few weeks. On Aug 30, 2013, the EC approved Aubagio as a once-daily treatment for adults suffering from RRMS.

Sanofi carries a Zacks Rank #5 (Strong Sell). We are concerned about generic erosion confronting most of Sanofi’s key drugs. Additionally, recent pipeline failures (oncology candidate - iniparib and anticoagulant - otamixaban) have put immense pressure on Sanofi’s pipeline.

Not all large-cap pharma companies are performing as badly as Sanofi. Novo Nordisk (NVO - Analyst Report), Roche (RHHBY - Analyst Report) and Bayer (BAYRY - Analyst Report) are well placed with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +5.57%
ENLINK MIDST ENLC 36.74 +2.86%
FEDERAL SIGN FSS 15.42 +2.12%
BNC BANCORP BNCN 17.41 +2.05%
EXTERRAN HLD EXH 45.06 +2.04%